Taselisib |
|
| Synonyms: 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide; GDC-0032; RG7604; | |
| Cat. No.: T13000 | CAS No.: 1282512-48-4 |
| MDL.: | Formula: C24H28N8O |
| F.W.460.53 | Purity: 99% |
| Storage: | |
| Size/Unit | Price | Qty | Availability | Price Total |
|---|---|---|---|---|
| 5mg | $129.00 | Enter qty and click checkbox |
 
|
$129.00 |
| Catalog Number： | T13000 | CAS No.: | 1282512-48-4 | |
| MDL: | Formula: | C24H28N8O | ||
| F.W.: | 460.53 | Purity: | 99% | |
| Package: | Unit: | mg | ||
| Appearance: | M.P.: | |||
| B.P.: | Density: | |||
| Optical Rotation: | Refractive Index: | |||
| Solubility: | DMSO | Stability: | ||
| Storage: | Category: | Reference Standard | ||
| Reference: | Lopez S, et al., Gynecol Oncol. 2014;135:312-317;Ndubaku CO et. al., J. Med Chem. 2013;56:4597-4610 | |||
| Application: | Taselisib is an investigational PI3K inhibitor currently being studied for its potential to selectively inhibit the PI3Ka isoform; it is designed to bind to the ATP-binding pocket of PI3Ka to potentially prevent subsequent downstream signaling; GDC-0032 is a potent, next-generation ß isoform-sparing PI3K inhibitor targeting PI3Ka/d/? with Ki of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kß. | |||